Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peg10 antisense oligonucleotide
- Development stage
- Preclinical
- Lead developer
- Vancouver Prostate Centre
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
PEG10 antisense oligonucleotide is an experimental RNA-targeted therapeutic designed to selectively inhibit the expression of Paternally Expressed Gene 10 (PEG10). PEG10 is a retrotransposon-derived protein that is typically silenced in adult tissues but frequently reactivated in various malignancies, including neuroendocrine-like muscle-invasive bladder cancer (MIBC), hepatocellular carcinoma, and neuroendocrine prostate cancer. The ASO functions by binding to PEG10 mRNA, which triggers its degradation and subsequently reduces PEG10 protein levels. Preclinical research indicates that silencing PEG10 can resensitize cancer cells to chemotherapy, induce cell cycle arrest by increasing p21 and p27 levels, and decrease the expression of epithelial-mesenchymal transition (EMT) markers such as SLUG and SNAIL, thereby inhibiting tumor growth, invasion, and metastasis.
- Other names
- PEG10 ASOPEG-10 ASOPEG 10 ASOASO-PEG10ASO-PEG-10ASO-PEG 10
02
Targets
PEG10 (Paternally expressed 10 (PEG10) mRNA)
Beyond the preview
Go deeper on peg10 antisense oligonucleotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peg10 antisense oligonucleotide.